A European, multicenter, real-world study directly comparing for the 1st time the effectiveness of safinamide vs. rasagiline and other standard of care (SoC) drugs in Parkinson's Disease

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jul 2020 New trial record
26 May 2020 According to a trial design presented at the 6th Congress of the European Academy of Neurology, a total of 1235 patients already on treatment for no more than 2 months will be enrolled in 135 centers across Belgium, Germany, Italy, Spain and United Kingdom and will be followed for 1 year. results are expected by 2021.
26 May 2020 Trial design presented at the 6th Congress of the European Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com